Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as one of the most significant advances in weight management in decades. Originally developed for type 2 diabetes, these medications have shown remarkable efficacy in helping patients achieve sustainable weight loss.
GLP-1 is a naturally occurring hormone produced in the gut after eating. It signals the brain to reduce appetite, slows gastric emptying, and enhances insulin secretion. GLP-1 receptor agonists mimic this hormone, amplifying its effects for therapeutic benefit.
Medications like semaglutide and tirzepatide work by binding to GLP-1 receptors in the hypothalamus, the brain region that controls hunger and satiety. Clinical trials have demonstrated average weight loss of 15-20% of body weight over 68 weeks — results previously achievable only through bariatric surgery.
For compounding pharmacies, GLP-1 medications represent an opportunity to provide personalized formulations. Compounded versions can be tailored to individual dosing schedules, combined with supportive nutrients like B12, and prepared in patient-friendly concentrations that commercial products may not offer.
Providers considering GLP-1 therapy for their patients should be aware of common side effects including nausea, constipation, and reduced appetite — which are typically dose-dependent and improve over time. Gradual dose titration is key to patient compliance and comfort.
At Logos RX, we compound GLP-1 formulations under rigorous quality controls. Our pharmacists work directly with providers to customize concentrations and dosing protocols that align with each patient's unique treatment plan.
Questions about this topic?
Our pharmacists are available to consult with providers and answer questions about formulations, dosing, and patient care.